^
    Back
    Association details:
    Biomarker:PD-L1 overexpression
    Cancer:Acute Myelogenous Leukemia
    Drug:flotetuzumab (MGD006) (CD3 agonist, CD123 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    ASH 2019
    Title:

    Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients

    Published date:
    11/06/2019
    Excerpt:
    Lastly, post treatment biopsy PD-L1 expression was higher in non-responders than CR (23% vs 16%).
    DOI:
    10.1182/blood-2019-128485